Thomas A. Hensing, MD
Although an optimal treatment approach has yet to be identified for patients with stage III non–small cell lung cancer (NSCLC), Thomas Hensing, MD, explained that significant progress has been made with the introduction of immunotherapy agents to the field.
on Advanced Non–Small Cell Lung Cancer, Hensing discussed the emergence of immunotherapy in the stage III NSCLC armamentarium, and questions that must be answered to build on this initial success.
OncLive: What are the currently available treatment options for patients with stage IIIa NSCLC?
: For most patients who come in with stage III disease—a disease that’s locally advanced within the chest—we treat it with a combination of modalities. Most patients will likely be treated with some kind of chemotherapy and radiation. The biggest new addition to that is now—at least for some patients—immune checkpoint inhibitors that have recently been shown to significantly improve OS.
What trials have evaluated the use of immune checkpoint inhibitors in this population?
A significant landmark study that was just published was the PACIFIC trial. In that study, they randomized patients who came in with stage III disease that was not operable; these patients had received chemotherapy and radiation and were randomized to 1 year of durvalumab versus placebo. What they showed last year was that the progression free survival (PFS) rate in patients improved significantly by more than 11 months.
was the OS data, which were significantly in favor of durvalumab.
Is there knowledge about which patients do not respond to durvalumab?
One of the common biomarkers that we test for is called PD-L1, and that testing was done on the majority of patients on the study, but it was not required. Therefore, for about one-third of patients who were on the study, we don’t have information pertaining to their PD-L1 status. The authors did go back and look at the benefit based on expression of PD-L1, but the trial itself was designed as an all-comers study, and the benefit was seen across the board.
Based on some post-hoc analyses, the question came up about whether patients whose tumors don’t express PD-L1 truly benefit from this approach. That would be one area that we’re going to need to know that about our patients, and that’s definitely one subset for whom we really need to continue to put on clinical trials to decide on the best approach. For those patients who don’t have tumors with PD-L1 expression, should we be doing something different?
What are the next steps with immunotherapy research in this setting?
We will all look at the PACIFIC trial as the landmark study that served as proof of principle that this strategy can help patients. As beneficial as it was, we’re still not curing everybody, so there’s still room for improvement and a lot of questions that remain to be answered. This is step one, but it is definitely a significant step in the right direction.
... to read the full story